OSLIF

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland

Active ingredients

The drug OSLIF contains one active pharmaceutical ingredient (API):

1 Indacaterol UNII 2JEC1ITX7R - INDACATEROL MALEATE

Indacaterol is a partial agonist at the human beta2-adrenergic receptor with nanomolar potency. When inhaled, indacaterol acts locally in the lung as a bronchodilator. In isolated human bronchus, indacaterol has a rapid onset of action and a long duration of action. Read about Indacaterol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03AC18	Indacaterol	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AC Selective beta-2-adrenoreceptor agonists
Discover more medicines within R03AC18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1451999, 1452002, 1452013, 1452024, 1452035, 1452103, 1452114, 1452125, 1452136, 1452147
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 09586002, 09586007
Country: FR	Base de données publique des médicaments	Identifier(s): 61742500, 68637167
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1052390, 1052391, 1052392, 1052393, 1052394, 1052395, 1052396, 1052397, 1052398, 1052399
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100248725, 100248731